Brokers Set Expectations for Regenxbio Inc’s FY2018 Earnings (RGNX)

Regenxbio Inc (NASDAQ:RGNX) – Leerink Swann issued their FY2018 EPS estimates for Regenxbio in a research note issued to investors on Tuesday, November 27th. Leerink Swann analyst M. Foroohar forecasts that the biotechnology company will post earnings per share of $2.37 for the year. Leerink Swann currently has a “Underperform” rating and a $42.00 price objective on the stock. Leerink Swann also issued estimates for Regenxbio’s Q4 2018 earnings at ($0.46) EPS, Q1 2019 earnings at ($0.63) EPS, Q2 2019 earnings at ($0.63) EPS, Q3 2019 earnings at ($0.63) EPS, Q4 2019 earnings at ($0.63) EPS, FY2019 earnings at ($2.52) EPS, FY2020 earnings at ($1.80) EPS and FY2021 earnings at $1.25 EPS.

A number of other equities research analysts also recently issued reports on RGNX. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 price objective for the company in a research report on Wednesday, November 7th. BidaskClub downgraded shares of Regenxbio from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. ValuEngine raised shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. Raymond James set a $96.00 price objective on shares of Regenxbio and gave the company a “buy” rating in a research report on Thursday, November 8th. Finally, Bank of America boosted their price objective on shares of Regenxbio from $76.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $77.81.

NASDAQ:RGNX opened at $59.91 on Friday. Regenxbio has a 12 month low of $23.25 and a 12 month high of $85.10. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of -24.45, a P/E/G ratio of 9.21 and a beta of -0.49.

Regenxbio (NASDAQ:RGNX) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.30. Regenxbio had a net margin of 44.30% and a return on equity of 22.52%. The business had revenue of $5.31 million during the quarter.

In related news, SVP Patrick J. Christmas sold 5,000 shares of Regenxbio stock in a transaction on Thursday, October 18th. The shares were sold at an average price of $61.78, for a total transaction of $308,900.00. Following the transaction, the senior vice president now owns 22,669 shares in the company, valued at approximately $1,400,490.82. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Vittal Vasista sold 7,500 shares of Regenxbio stock in a transaction on Monday, September 17th. The shares were sold at an average price of $74.86, for a total transaction of $561,450.00. Following the transaction, the chief financial officer now owns 120,722 shares in the company, valued at approximately $9,037,248.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 436,170 shares of company stock valued at $28,071,956. Insiders own 16.90% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Riverhead Capital Management LLC lifted its stake in shares of Regenxbio by 137.5% during the 3rd quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 1,100 shares in the last quarter. Meadow Creek Investment Management LLC purchased a new position in shares of Regenxbio during the 2nd quarter valued at $141,000. Meeder Asset Management Inc. lifted its stake in shares of Regenxbio by 1,212.0% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,178 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 2,012 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Regenxbio during the 2nd quarter valued at $157,000. Finally, Glen Harbor Capital Management LLC purchased a new position in shares of Regenxbio during the 2nd quarter valued at $171,000. Institutional investors own 75.92% of the company’s stock.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Story: How is a Moving Average Calculated?

Earnings History and Estimates for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit